← back to search

Kristina Navrazhina

Weill Cornell Medicine · US
Area of research
Dermatology · Surgery
Research interest
Research interests include Hidradenitis Suppurativa and Treatments, Colorectal and Anal Carcinomas, Acne and Rosacea Treatments and Effects, and Anorectal Disease Treatments and Outcomes.
h-index
24
citations
2,568
works
84
NIH funding
primary concept
Hidradenitis suppurativa
email

Recent publications

Gram‐negative anaerobes elicit a robust keratinocytes immune response with potential insights into <scp>HS</scp> pathogenesis
Experimental Dermatology 2024cited by 24position: middledoi
Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape
British Journal of Dermatology 2023cited by 94position: middledoi
<scp>Interleukin‐17RA</scp> blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum
British Journal of Dermatology 2022cited by 51position: firstdoi
Ustekinumab reduces serum protein levels associated with cardiovascular risk in psoriasis vulgaris
Experimental Dermatology 2022cited by 18position: middledoi
Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa
Journal of Allergy and Clinical Immunology 2021cited by 125position: firstdoi
In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes
Journal of Investigative Dermatology 2021cited by 57position: firstdoi
The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris
Journal of the American Academy of Dermatology 2021cited by 48position: firstdoi
Large‐scale serum analysis identifies unique systemic biomarkers in psoriasis and hidradenitis suppurativa*
British Journal of Dermatology 2021cited by 43position: firstdoi
High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression
Journal of Allergy and Clinical Immunology 2021cited by 38position: firstdoi
Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation
Cancer Cell 2020cited by 159position: middledoi
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Journal for ImmunoTherapy of Cancer 2020cited by 122position: middledoi
The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study
Journal of the American Academy of Dermatology 2020cited by 114position: middledoi
Contribution of fibroblasts to tunnel formation and inflammation in hidradenitis suppurativa/ acne inversa
Experimental Dermatology 2019cited by 59position: middledoi
Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease
Journal of Clinical Investigation 2012cited by 730position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

James G. Krueger · University of Rochester Medical Center11 papers (2019–2024)John W. Frew · UNSW Sydney10 papers (2019–2024)Sandra Garcet · Rockefeller University9 papers (2020–2024)Juana Gonzalez · Rockefeller University5 papers (2021–2024)David Grand · Brown University4 papers (2020–2022)Hong Hur · Rockefeller University3 papers (2021–2024)Samuel C. Williams · Rockefeller University3 papers (2021–2024)Mary Sullivan‐Whalen · Rockefeller University2 papers (2020–2021)Xiuzhong Zheng · Rockefeller University2 papers (2021–2021)Patricia Gilleaudeau · Rockefeller University2 papers (2020–2021)Shunsuke Miura · Rockefeller University1 papers (2024–2024)Joseph Han · Eastern Virginia Medical School1 papers (2022–2022)Kerstin Wolk · Humboldt-Universität zu Berlin1 papers (2023–2023)Alexa B. Kimball · Tufts University1 papers (2023–2023)Azeb Tadesse Argaw · Icahn School of Medicine at Mount Sinai1 papers (2012–2012)Meaghan Marohn · New York University1 papers (2019–2019) · 1 papers (2023–2023) · 1 papers (2023–2023)Michael Garshick · NYU Langone Health1 papers (2022–2022)Dipankar J. Dutta · Gladstone Institutes1 papers (2012–2012)